Funding Announcements

"We’re still diagnosing in the twenty-first century with a test invented in the 1800s, and one that needs specialist equipment and training most of the world doesn’t have access to. Lower-income and minority communities pay the price for that first. That’s the gap we want to close at TidalSense, and the NHS is the first place we’re doing it,"

"Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer. Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients, and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape."

"This funding marks a defining moment for Zonova. We founded the company with the belief that infection prevention in medical devices needed a fundamentally new approach, one that moves beyond coatings, antibiotics, and short term fixes. Our technology has the potential to redefine how medical devices are designed globally by embedding antimicrobial protection directly into the material itself. THENA Capital immediately understood both the scale of the clinical problem and the magnitude of the commercial opportunity. The THENA team brings an exceptional combination of scientific depth, strategic insight, and operational ambition that is incredibly rare in venture. We are thrilled to have them leading this round and joining us as we scale toward major OEM partnerships and international deployment."

"The problem we are solving exists across every clinical setting that uses a pulse oximeter, and the litigation and regulatory pressure on manufacturers is accelerating. EarMetrics® offers them a technically credible, racially inclusive, licensable solution."

"The decision by our existing shareholders to reinvest, and to do so at a level that exceeded our target, speaks directly to their confidence in what PlaqueTec’s data is revealing about cardiovascular disease. We are building something genuinely differentiated: a high-resolution, intracoronary data asset that is poised to underpin the next generation of cardiovascular therapeutics. This round validates that strategy and gives us the runway to prove it."